|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.04.26 - 22:06
|
NeoGenomics Reports First Quarter 2026 Results (Business Wire)
|
|
|
First quarter total revenue increased 11% YoY to $187 million;
Clinical revenue grew 14%, including NGS growth of 26%;
Company announces increase in full-year 2026 revenue guidance to a range of $797-$803 millionFORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first quarter results for the period ended March 31, 2026.
First Quarter 2026 Financial Highlights As Compared To First Quarter 2025
Consolidated revenue increased 11% to a first quarter record $187 million, driven by Clinical revenue growth of 14%
Net loss decreased 34% to $17 million
Adjusted EBITDA(1) was positive $9 million, an increase of 27% from prior year
First Quarter 2026 Operating Highlights
Launched RaDaR® ST, a circulating tumor DNA (ctDNA) assay for detecting molecular residual disease (MRD), which we estimate represents a $20 billion addressable market, growing at 30% annually, ...
|
|
|
|
|
|
|
07.04.26 - 13:06
|
NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026 (Business Wire)
|
|
|
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Tuesday, April 28, 2026. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. Beginning with Q1 2026, NeoGenomics will hold quarterly results calls after market close to allow time for follow-up discussions before the next trading day.
The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call.
To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code is 750346.
About NeoGenomics,...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17.02.26 - 13:12
|
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results (Business Wire)
|
|
|
Full-year revenue increased 10% to $727 million;
Full-year clinical revenue grew 15%, or 13% excluding the Pathline acquisition;
Successfully resolved RaDaR ST patent litigationFORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its fourth-quarter and full-year results for the period ended December 31, 2025.
Fourth Quarter and Full Year 2025 Highlights
Fourth quarter consolidated revenue increased 11% to $190 million; Full-year consolidated revenue increased 10% to $727 million
Fourth quarter net loss decreased 36% to $10 million; Full-year net loss increased 37% to $108 million
Fourth quarter adjusted EBITDA(1) increased 13% to positive $13 million; Full year adjusted EBITDA increased 9% to positive $43 million
“We ended 2025 on a strong note, delivering double-digit revenue growth in the fourth quarter on the strength of our clinical volumes and ongoing mix shift t...
|
|
|
|
|
27.01.26 - 13:06
|
NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 (Business Wire)
|
|
|
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Tuesday, February 17, 2026. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights.
The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call.
To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code is 825997.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
